Maven Securities LTD Sells 100,000 Shares of Liquidia Co. (NASDAQ:LQDA)

Maven Securities LTD cut its holdings in Liquidia Co. (NASDAQ:LQDA - Free Report) by 33.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 200,000 shares of the company's stock after selling 100,000 shares during the quarter. Maven Securities LTD owned 0.24% of Liquidia worth $2,352,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC bought a new stake in Liquidia during the fourth quarter valued at about $59,000. Summit Investment Advisors Inc. boosted its holdings in shares of Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock valued at $78,000 after buying an additional 1,719 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in Liquidia during the 4th quarter worth about $142,000. EntryPoint Capital LLC acquired a new position in shares of Liquidia in the 4th quarter valued at $154,000. Finally, Bayesian Capital Management LP purchased a new stake in Liquidia during the 4th quarter worth approximately $163,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Stock Up 3.2%

LQDA opened at $15.75 on Tuesday. The stock has a market cap of $1.35 billion, a P/E ratio of -9.66 and a beta of 0.24. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.81. The company has a fifty day simple moving average of $14.25 and a 200 day simple moving average of $13.21.

Liquidia (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, equities research analysts expect that Liquidia Co. will post -1.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Raymond James upped their target price on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research note on Friday. Needham & Company LLC reiterated a "buy" rating and issued a $25.00 target price on shares of Liquidia in a report on Monday. Scotiabank restated an "outperform" rating on shares of Liquidia in a report on Monday, May 5th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $29.00 price target on shares of Liquidia in a report on Monday. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $27.13.

Insider Transactions at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 5,964 shares of the business's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total value of $80,931.48. Following the sale, the general counsel now directly owns 570,301 shares in the company, valued at $7,738,984.57. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Rajeev Saggar sold 2,450 shares of the firm's stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $13.67, for a total value of $33,491.50. Following the completion of the sale, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. The trade was a 0.92% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,138 shares of company stock worth $450,233. Company insiders own 26.50% of the company's stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.